ACADIA Acquires CerSci Therapeutics for $52.5M
Shots: ACADIA acquires all outstanding shares of CerSci for $52.5M. CerSci may receive up to $887M as development, commercialization milestones along with royalties on sales The acquisition will boost ACADIA’s clinical pipeline with the addition of non-opioid pain therapies including CerSci’s lead candidate ACP-044 ACP-044 has demonstrated a promising effect in the P-I study with an […]